Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials

Author(s): Hadeer Mohamed, Mostafa Eltobgy, Omar Abdel-Rahman*

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 17 , Issue 9 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Malignant pleural mesothelioma (MPM) is a hard to treat malignancy arising from the mesothelial surface of the pleura. Immune checkpoint inhibitors are considered a promising therapeutic strategy in many hardto- treat malignancies. In this review, we are trying to provide an in depth coverage of the prognostic value of immune checkpoints aberrations as well as discuss the different novel therapeutic strategies implementing these agents in the management of MPM.

Keywords: Mesothelioma, tremelimumab, ipilimumab, pembrolizumab, immune, prognostic value.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [1228 - 1233]
Pages: 6
DOI: 10.2174/1871520617666170102151918
Price: $65

Article Metrics

PDF: 35